4,901 trials
Solid Tumor · Osteosarcoma
Primary: Dose Escalation Part: Number of Dose-Limiting Toxicities (DLTs) at Each Dose Level on Cycle 1 — 0; 2 Number of DLTs
Healthy Study Participants
Primary: Maximum Plasma Concentration at Steady State [Cmax(ss)] After Multiple Doses of Brivaracetam — 2.963; 2.878 microgram per milliliter (μg/mL)
Dermatitis, Atopic
Primary: Number of Participants Who Experience One or More Adverse Events (AEs) — 13; 6; 30; 9 Participants
Polytrauma
Primary: Length of Hospital Stay — 7; 8 days — p==0.275
Soft Tissue Sarcoma · Mesothelioma
Primary: Maximum Tolerated Dose of Temozolomide — 200 mg/m^2
Methemoglobinemia · Congenital Methemoglobinemia
Primary: Area Under the Curve (AUC) From Time Zero to the Time of Last Quantifiable Concentration (AUC 0-t) — 2600.09 ng*hr/mL
Acute Lymphoblastic Leukemia (ALL)
Primary: Phase 1b: Number of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs) — 5; 6; 3; 7 Participants
Lymphoma, Non-Hodgkin · Leukemia, Lymphocytic, B Cell · B-Cell Lymphoma
Primary: Grades of Toxicity by Type of Toxicity — 2; 2; 1; 1 toxicities
Healthy Volunteer
Primary: Incidence of Adverse Events — 1; 1; 0; 1 events
Multiple Sclerosis (MS) · Relapsing Remitting Multiple Sclerosis
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 2; 1; 3; 9 Participants
Neoplasms
Primary: Number of Participants Who Experienced a Dose-Limiting Toxicity (DLT) — 0; 0; 0; 0 Participants
Acute Respiratory Failure
Primary: Number of Treatment-Emergent Severe Adverse Events [Safety] — 0; 0 number of safety events
Chemotherapy-Induced Alopecia
Primary: Dose-limiting Toxicities (DLT) of Topical Compound 31543 — 0; 0; 0; 0 Participants
COVID-19
Primary: Number of Participants With Any Solicited Administration Site Events — 8; 0; 10; 1 Participants
Healthy Adult Subjects
Primary: To Demonstrate the PK Similarity of AVT05 With US Licensed and EU Approved Simponi and the PK of EU Approved Simponi With US Licensed Simponi — 3453.8; 3468.6; 3567.1…